指南与共识临床试验与 GCP流行病学与生物统计

ANCA相关性血管炎患者血浆置换与糖皮质激素剂量:临床实践指南

Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.
指南 / 共识 · BMJ · 2022-02-25

该指南针对ANCA相关性血管炎(AAV)诱导治疗前6个月,回答血浆置换的作用及糖皮质激素最佳剂量。基于两项系统评价,指南对低或低中度终末期肾病(ESKD)风险者弱推荐反对血浆置换,对中高度或高度风险者弱推荐支持血浆置换;对无肾脏受累的肺出血建议不血浆置换(弱推荐);强推荐采用减少剂量而非标准剂量糖皮质激素方案。

要点

  • 低或低中度ESKD风险者,弱推荐反对血浆置换;中高度或高度风险者,弱推荐支持血浆置换。
  • 无肾脏受累的肺出血患者,建议不进行血浆置换(弱推荐)。
  • 强推荐采用减少剂量糖皮质激素方案,而非标准剂量方案。

核心结论

  • 对低或低中度ESKD风险的AAV患者,弱推荐反对血浆置换;对中高度或高度风险者,弱推荐支持血浆置换。
  • 对无肾脏受累的肺出血患者,建议不进行血浆置换(弱推荐)。
  • 强推荐采用减少剂量糖皮质激素方案,而非标准剂量方案,该方案在治疗前6个月减量更快且累积剂量更低。

研究设计与样本

  • 指南小组由患者、照护者、临床医生、内容专家和方法学家组成,采用GRADE方法并遵循可信指南标准制定推荐。
  • 推荐基于两项关联的系统评价,小组从个体患者视角制定推荐。

主要发现

  • 血浆置换系统评价纳入9项随机对照试验(RCT),共1060例AAV患者;血浆置换对死亡率或疾病复发可能几乎没有影响(中等和低确定性)。
  • 血浆置换可能降低1年ESKD风险:低风险约降低0.1%,低中度风险约降低2.1%,中高度风险约降低4.6%,高风险或需透析者约降低16.0%。
  • 血浆置换可能增加1年严重感染风险:低风险约增加2.7%,低中度风险约增加4.9%,中高度风险约增加8.5%,高风险组约增加13.5%(中等至高确定性)。
  • 对无肾脏受累的肺出血患者,基于间接证据,血浆置换对死亡可能几乎没有影响(极低确定性),但可能重要增加1年严重感染(约增加6.8%,低确定性)。
  • 糖皮质激素剂量系统评价纳入2项低偏倚风险RCT,分别有704例和140例患者;减少剂量方案可能降低严重感染风险约5.9%至12.8%,且可能不增加6个月至超过1年随访的ESKD风险(两项结局均为中等确定性)。

关键数值与推荐

  • 低或低中度ESKD风险:弱推荐反对血浆置换。
  • 中高度或高度ESKD风险:弱推荐支持血浆置换。
  • 无肾脏受累的肺出血:建议不进行血浆置换(弱推荐)。
  • 减少剂量糖皮质激素方案:强推荐支持,而非标准剂量方案。

临床怎么用

  • 指南推荐基于患者对减少ESKD的高度重视和对避免严重感染的较低重视。
  • 小组估计50-90%充分知情的低或低中度ESKD风险AAV患者(伴或不伴肺出血)会拒绝血浆置换。
  • 大多数中高度或高度风险或需透析的患者(伴或不伴肺出血)会选择接受血浆置换。
  • 大多数无肾脏受累的肺出血充分知情患者会拒绝血浆置换。
  • 全部或几乎全部(≥90%)充分知情的AAV患者会在治疗前6个月选择减少剂量糖皮质激素方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CLINICAL QUESTIONS: What is the role of plasma exchange and what is the optimal dose of glucocorticoids in the first 6 months of therapy of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)? This guideline was triggered by the publication of a new randomised controlled trial. CURRENT PRACTICE: Existing guideline recommendations vary regarding the use of plasma exchange in AAV and lack explicit recommendations regarding the tapering regimen of glucocorticoids during induction therapy. RECOMMENDATIONS: The guideline panel makes a weak recommendation against plasma exchange in patients with low or low-moderate risk of developing end stage kidney disease (ESKD), and a weak recommendation in favour of plasma exchange in patients with moderate-high or high risk of developing ESKD. For patients with pulmonary haemorrhage without renal involvement, the panel suggests not using plasma exchange (weak recommendation). The panel made a strong recommendation in favour of a reduced dose rather than standard dose regimen of glucocorticoids, which involves a more rapid taper rate and lower cumulative dose during the first six months of therapy. HOW THIS GUIDELINE WAS CREATED: A guideline panel including patients, a care giver, clinicians, content experts, and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. The recommendations are based on two linked systematic reviews. The panel took an individual patient perspective in the development of recommendations. THE EVIDENCE: The systematic review of plasma exchange identified nine randomised controlled trials (RCTs) that enrolled 1060 patients with AAV. Plasma exchange probably has little or no effect on mortality or disease relapse (moderate and low certainty). Plasma exchange probably reduces the one year risk of ESKD (approximately 0.1% reduction in those with low risk, 2.1% reduction in those with low-moderate risk, 4.6% reduction in those with moderate-high risk, and 16.0% reduction in those with high risk or requiring dialysis) but increases the risk of serious infections (approximately 2.7% increase in those with low risk, 4.9% increase in those with low-moderate risk, 8.5% increase in those with moderate-high risk, to 13.5% in high risk group) at 1 year (moderate to high certainty). The guideline panel agreed that most patients with low or low-moderate risk of developing ESKD would consider the harms to outweigh the benefits, while most of those with moderate-high or high risk would consider the benefits to outweigh the harms. For patients with pulmonary haemorrhage without kidney involvement, based on indirect evidence, plasma exchange may have little or no effect on death (very low certainty) but may have an important increase in serious infections at 1 year (approximately 6.8% increase, low certainty). The systematic review of different dose regimens of glucocorticoids identified two RCTs at low risk of bias with 704 and 140 patients respectively. A reduced dose regimen of glucocorticoid probably reduces the risk of serious infections by approximately 5.9% to 12.8% and probably does not increase the risk of ESKD at the follow-up of 6 months to longer than 1 year (moderate certainty for both outcomes). UNDERSTANDING THE RECOMMENDATION: The recommendations were made with the understanding that patients would place a high value on reduction in ESKD and less value on avoiding serious infections. The panel concluded that most (50-90%) of fully informed patients with AAV and with low or low-moderate risk of developing ESKD with or without pulmonary haemorrhage would decline plasma exchange, whereas most patients with moderate-high or high risk or requiring dialysis with or without pulmonary haemorrhage would choose to receive plasma exchange. The panel also inferred that the majority of fully informed patients with pulmonary haemorrhage without kidney involvement would decline plasma exchange and that all or almost all (≥90%) fully informed patients with AAV would choose a reduced dose regimen of glucocorticoids during the first 6 months of therapy.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Zeng L, Walsh M, Guyatt GH, et al. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ. 2022. PMID: 35217581. doi:10.1136/bmj-2021-064597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。